



# Physician Prescription/Order & Statement of Medical Necessity



1. First prescription for the patient: Fax completed form to 1-866-565-7794  
 2. Subsequent prescription: May be e-script via **EVERSANA Life Science Services Specialty Pharmacy** in your EMR/HMR system  
 Call 1-866-758-7071 if you have questions regarding this form or contact Chiesi Total Care<sup>SM</sup>

## PATIENT INFORMATION

Patient Name (Last, First) \_\_\_\_\_ Email \_\_\_\_\_  
 Social Security # \_\_\_\_\_ - \_\_\_\_\_ - \_\_\_\_\_ Sex:  Male  Female Date of Birth \_\_\_\_\_ (mm/dd/yyyy)  
 Address \_\_\_\_\_ City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
 Primary Phone (Required) \_\_\_\_\_ Cell Phone \_\_\_\_\_ Language:  English  Other \_\_\_\_\_

Please attach copies of patient insurance and prescription cards – front and back.

## MEDICAL INFORMATION

Diagnosis:  Transfusional Iron Overload E83.111  
 Due to:  Beta Thalassemia D56.1  Other Thalassemias D56.8  Other Anemias \_\_\_\_\_  
 Sickle Cell Disease D57.1  Other Sickle Cell Disease D57.8  Other \_\_\_\_\_  
 Height \_\_\_\_\_ inches or \_\_\_\_\_ cm **Weight** \_\_\_\_\_ lb or \_\_\_\_\_ kg Allergies:  None or Specify \_\_\_\_\_

Lab test	Results	Date (mm/dd/yyyy)
Most recent serum ferritin level (target level <500 ng/mL)		

If available please provide the following	Results	Date (mm/dd/yyyy)
Most recent liver iron concentration value (target level <3,000 µg/g dry weight)		
Most recent cardiac MRI T2* value (target level >20 ms)		

Prior Chelation Therapy \_\_\_\_\_ Current Chelation Therapy \_\_\_\_\_

### Transfusion History

Approximate number of blood units/month	
Approximate interval between transfusions (weeks)	

## FERRIPROX® (DEFERIPRONE) PRESCRIPTION/ORDER

### TWICE-A-DAY FORMULATION

Ferriprox (deferiprone) Twice-A-Day tablets 1000 mg<sup>†</sup>

Sig: Take \_\_\_\_\_ tablets po BID

### THREE-TIMES-A-DAY FORMULATION<sup>†</sup>

Ferriprox (deferiprone) oral solution 100 mg/mL

Sig: Take \_\_\_\_\_ mL po TID or see Rx attached

<sup>†</sup> 500 mg and 1000 mg Three-Times-A-Day tablets are still available. Talk to your pharmacist for more information.

(Standard dose is 75-99 mg/kg/day divided into 2 doses/day for Twice-A-Day tablets or 3 doses/day for oral solution.) **Dispense 30-day supply.**

Number of Refills \_\_\_\_\_

## PHYSICIAN/OFFICE INFORMATION

Prescriber's Name (print) \_\_\_\_\_ Office Phone \_\_\_\_\_  
 Prescriber's Email \_\_\_\_\_ Office Fax \_\_\_\_\_  
 Practice/Group Name \_\_\_\_\_ License # \_\_\_\_\_  
 Address \_\_\_\_\_ Suite \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_  
 City \_\_\_\_\_ NPI # \_\_\_\_\_  
 Office Contact Person \_\_\_\_\_

By signing below, I certify that I am part of the Chiesi Total Care Program, that the therapy described above is medically necessary, and that the information provided is accurate to the best of my knowledge. I also attest that I have obtained the patient's authorization to release the above information and such other personal information as may be necessary to the Chiesi Total Care Program and/or their agents. If the patient is 18 years old or younger, I attest that I have obtained permission from the patient's legal guardian.

Prescriber's Signature \_\_\_\_\_ Date \_\_\_\_\_

Substitution Permitted

Dispense as Written

Ferriprox Twice-A-Day is available as 1000 mg BID tablets.  
 Ferriprox is available as 1000 mg and 500 mg (immediate release) Three-Times-A-Day tablets  
 and as 100 mg/mL oral solution.

Please see Important Safety Information, including boxed WARNING, on the back.

Scan for digital RX form.



## Indication

Ferriprox® (deferiprone) is an iron chelator indicated for the treatment of transfusional iron overload in patients with:

- thalassemia syndromes
- sickle cell disease or other anemias

Ferriprox Tablets are indicated in adult and pediatric patients ≥8 years of age; Ferriprox Oral Solution is indicated in patients ≥3 years of age.

## Limitations of Use

Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia.

## Important Safety Information

### WARNING: AGRANULOCYTOSIS AND NEUTROPENIA

- Ferriprox can cause agranulocytosis that can lead to serious infections and death. Neutropenia may precede the development of agranulocytosis.
- Measure the absolute neutrophil count (ANC) before starting Ferriprox and monitor regularly while on therapy.
- Interrupt Ferriprox therapy if neutropenia develops.
- Interrupt Ferriprox if infection develops, and monitor the ANC more frequently.
- Advise patients taking Ferriprox to report immediately any symptoms indicative of infection.

Ferriprox is contraindicated in patients with known hypersensitivity to deferiprone or to any of the excipients in the formulations.

In pooled clinical trials, 7.5% of 642 patients with thalassemia syndromes treated with Ferriprox developed increased ALT values. Four (0.62%) Ferriprox-treated subjects discontinued the drug due to increased serum ALT levels and 1 (0.16%) due to an increase in both ALT and AST. In pooled clinical trials, 7.7% of 196 patients with sickle cell disease or other anemias treated with Ferriprox developed increased ALT values. Monitor serum ALT values monthly during therapy with Ferriprox and consider interruption of therapy if there is a persistent increase in the serum transaminase levels. Decreased plasma zinc concentrations have been observed on deferiprone therapy. Monitor plasma zinc annually, and supplement in the event of a deficiency.

Ferriprox can cause fetal harm. Advise females of reproductive potential to use an effective method of contraception during treatment with Ferriprox and for at least six months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with Ferriprox and for at least three months after the last dose. Advise females not to breastfeed during treatment with Ferriprox and for at least 2 weeks after the last dose.

Avoid co-administration of Ferriprox with other drugs known to be associated with neutropenia or agranulocytosis; however, if this is unavoidable, closely monitor the absolute neutrophil count. Avoid co-administration with UGT1A6 inhibitors. Allow at least a 4-hour interval between administration of Ferriprox and drugs or supplements containing polyvalent cations (e.g., iron, aluminum, or zinc).

The most common adverse reactions in patients with thalassemia (incidence ≥6%) are nausea, vomiting, abdominal pain, arthralgia, ALT increased and neutropenia. The most common adverse reactions in patients with sickle cell disease or other anemias (incidence ≥6%) are pyrexia, abdominal pain, bone pain, headache, vomiting, pain in extremity, sickle cell anemia with crisis, back pain, ALT increased, AST increased, arthralgia, oropharyngeal pain, nasopharyngitis, neutrophil count decreased, cough and nausea.

Inform patients that their urine might show a reddish/brown discoloration due to the excretion of the iron-deferiprone complex. This is a very common sign of the desired effect, and it is not harmful.

Advise patients to avoid alcohol while taking Ferriprox tablets (twice-a-day). Consumption of alcohol while taking Ferriprox tablets (twice-a-day) may result in more rapid release of deferiprone.

Please see full Prescribing Information, including boxed WARNING and Medication Guide.

*Chiesi Total Care Program offered through EVERSANA Life Science Services Specialty Pharmacy.*

### CHIESI TOTAL CARE



**PHONE**  
1-866-758-7071



**HOURS OF OPERATION**  
Monday to Friday  
7:00am - 6:00pm (Central Time)



**FAX**  
1-866-565-7794



**WEBSITE**  
chiesitotalcare.com

For more information, visit [ferriprox.com](http://ferriprox.com).

© Chiesi USA, Inc., 2024. All rights reserved.

Ferriprox® is a registered trademark of CHIESI FARMACEUTICI S.p.A.

Chiesi Total Care™ is a service mark of CHIESI FARMACEUTICI S.p.A.

PP-F-0131 V8.0 2024

